Longitudinal changes of serum COMP and urinary CTX-II predict X-ray defined knee osteoarthritis severity and stiffness in women

Osteoarthritis and Cartilage

Volumn 17, Issue 12, 2009, Pages 1609-1614

  Sowers, M F ^a   Karvonen Gutierrez, C A ^a   Yosef, M ^a   Jannausch, M ^a   Jiang, Y ^b   Garnero, P ^c   Jacobson, J ^b  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c INSERM   (France)

Author keywords

Biomarkers; COMP; CTX II; Functioning; Osteoarthritis; Pain; Stiffness

Indexed keywords

CARTILAGE OLIGOMERIC MATRIX PROTEIN; COLLAGEN TYPE 2;

ADULT; ARTICLE; BODY SIZE; BONE RADIOGRAPHY; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEASIBILITY STUDY; FEMALE; HUMAN; JOINT STIFFNESS; KNEE OSTEOARTHRITIS; KNEE PAIN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN URINE LEVEL; SCORING SYSTEM;

BIOLOGICAL MARKERS; CARTILAGE, ARTICULAR; EXTRACELLULAR MATRIX PROTEINS; FEASIBILITY STUDIES; FEMALE; GLYCOPROTEINS; HUMANS; KNEE JOINT; LONGITUDINAL STUDIES; MENOPAUSE; MICHIGAN; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PREDICTIVE VALUE OF TESTS;

EID: 70449627161     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2009.06.001     Document Type: Article

References (37)

1. Lohmander L.S., Saxne T., and Heinegard D.K. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Ann Rheum Dis 53 (1994) 8-13
2. Mansson B., Carey D., Alini M., Ionescu M., Rosenberg L.C., Poole A.R., et al. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 95 (1995) 1071-1077
3. Sharif M., Saxne T., Shepstone L., Kirwan J.R., Elson C.J., Heinegard D., et al. Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Br J Rheumatol 34 (1995) 306-310
4. Lorenzo P. Identification and characterization of a novel cartilage gene product CILP, which is an early indicator of osteoarthritis, dissertation, Lund (Sweden), Lund University, 1998.
5. Bleasel J.F., Poole A.R., Heinegard D., Saxne T., Holderbaum D., Ionescu M., et al. Changes in serum cartilage marker levels indicate altered cartilage metabolism in families with the osteoarthritis-related type II collagen gene COL2A1 mutation. Arthritis Rheum 42 (1999) 39-45
6. Petersson I.F., Boegard T., Svensson B., Heinegard D., and Saxne T. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. Br J Rheumatol 37 (1998) 46-50
7. Dahlberg L., Roos H., Saxne T., Heinegard D., Lark M.W., Hoerrner, et al. Cartilage metabolism in the injured and uninjured knee of the same patient. Ann Rheum Dis 53 (1994) 823-827
8. Sharif M., Kirwan J.R., Elson C.J., Granell R., and Clarke S. Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. Arthritis Rheum 50 (2004) 2479-2488
9. Vilim V., Olejarova M., Machacek S., Gatterova J., Kraus V.B., and Pavelka K. Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage 10 (2002) 707-713
10. Hunter D.J., Li J., LaValley M., Bauer D.C., Nevitt M., DeGroot J., et al. Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study. Arthritis Res Ther 9 (2007) R108
11. Garnero P., Piperno M., Gineyts E., Christgau S., Delmas P.D., and Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 60 (2001) 619-626
12. Sharif M., Kirwan J., Charni N., Sandell L.J., Whittles C., and Garnero P. A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis - association with disease progression. Rheumatology 46 (2007) 938-943
13. Reijman M., Hazes J.M., Bierma-Zeinstra S.M., Koes W., Christgau S., Christiansen C., et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 50 (2004) 2471-2478
14. Bruyere O., Collette J., Kothari M., Zaim S., White D., Genant H., et al. Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study. Ann Rheum Dis 65 (2006) 1050-1054
15. Dam E.B., Byrjalsen I., Karsdal M.A., Ovist P., and Christiansen C. Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage 17 (2009) 384-389
16. Lehmann H.J., Mouritzen U., Christgau S., Cloos P.A., and Chrisiansen C. Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 61 (2002) 530-533
17. Kellgren J.H., and Lawrence J.S. The Epidemiology of Chronic Rheumatism Volume II (1963), F.A. Davis, Philadelphia, PA
18. Buckland-Wright C. Protocols for precise radio-anatomical positioning of the tibiofemoral and patellofemoral compartments of the knee. Osteoarthritis Cartilage 3 Suppl A (1995) 71-80
19. Sowers M.F., Hayes C., Jamadar D., Capul D., Lachance L., Jannausch M., et al. Magnetic resonance-detected subchondral bone marrow and cartilage defect characteristics associated with pain and X-ray-defined knee osteoarthritis. Osteoarthritis Cartilage 11 (2003) 387-393
20. Bellamy N. WOMAC Osteoarthritis Index: a User's Guide. London (Canada): 1982.
21. Bellamy N. The WOMAC knee and hip osteoarthritis indices: development, validation, globalization and influence on the development of the AUSCAN hand osteoarthritis indices. Clin Exp Rheumatol 23 5 Suppl 39 (2005) S148-S153
22. Christgau S., Garnero P., Fledelius C., Moniz C., Ensig M., Gineyts E., et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 29 (2001) 209-215
23. Hanley J.A., and McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 (1982) 29-36
24. Saxne T., and Heinegård D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 31 (1992) 583-591
25. Neidhart M., Hauser N., Paulsson M., DiCesare P.E., Michel B.A., and Hauselmann H.J. Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation. Br J Rheumatol 36 (1997) 1151-1160
26. Fernandes F.A., Pucinelli M.L., da Silva N.P., and Feldman D. Serum cartilage oligomeric matrix protein (COMP) levels in knee osteoarthritis in a Brazilian population: clinical and radiological correlation. Scand J Rheumatol 36 (2007) 211-215
27. Vilim V., Vytasek R., Olejarova M., Machacek S., Gatterova J., Prochazka B., et al. Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage 9 (2001) 612-618
28. Muller G., Michel A., and Altenburg E. COMP (cartilage oligomeric matrix protein) is synthesized in ligament, tendon, meniscus, and articular cartilage. Connect Tissue Res 39 (1998) 233-244
29. Liu C.J., Kong W., Ilalov K., Yu S., Xu K., Prazak L., et al. ADAMTS-7: a metalloproteinase that directly binds to and degrades cartilage oligomeric matrix protein. FASEB J 20 (2006) 988-990
30. Mazieres B., Garnero P., Gueguen A., Abbal M., Berdah L., Leguesne M., et al. Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort. Ann Rheum Dis 65 (2006) 354-359
31. Mazzuca S.A., Brandt K.D., Eyre D.R., Katz B.P., Askew J., and Lane K.A. Urinary levels of type II collagen C-telopeptide crosslink are unrelated to joint space narrowing in patients with knee osteoarthritis. Ann Rheum Dis 65 (2006) 1055-1059
32. Oestergaard S., Sondergaard B., Hoegh-Andersen P., Henriksen K., Qvist P., Christiansen C., et al. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum 54 (2006) 2441-2451
33. Bay-Jensen A.C., Andersen T.L., Charni-Ben Tabassi N., Kristensen P.W., Kjaersgaard-Andersen P., Sandell L., et al. Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage. Osteoarthritis Cartilage 16 (2008) 615-623
34. Hayes C.W., Jamadar D.A., Welch G.W., Jannausch M.L., Lachance L.L., Capul D.C., et al. Osteoarthritis of the knee: comparison of MR imaging findings with radiographic severity measurements and pain in middle-aged women. Radiology 237 (2005) 998-1007
35. Garnero P., Ayral X., Rousseau J.C., Christgau S., Sandell L.J., Dougados M., et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 46 (2002) 2613-2624
36. Garnero P., Aronstein W.S., Cohen S.B., Conaghan P.G., Cline G.A., Christiansen C., et al. Relationships between biochemical markers of bone cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthritis Cartilage 16 (2008) 660-666
37. Jung M., Christgau S., Lukoschek M., Henriksen D., and Richter W. Increased urinary concentration of collagen Type II C-telopeptide fragments in patients with osteoarthritis. Pathobiology 71 (2004) 70-76